Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Low- and Favorable Intermediate-risk Prostate Cancer: SABR-Dual

NCT06027892 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT06027892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06027892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Low- and Favorable Intermediate-risk Prostate Cancer: SABR-Dual
Lead sponsor
Rabin Medical Center
Phase
Not applicable
Overall status
Recruiting
Start date
December 29, 2022
Completion date
December 31, 2032
Enrollment
562 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer